Suvratoxumab Reduces Staphylococcus Aureus Pneumonia in High-Risk ICU Patients: Results of the SAATELLITE Study
Bruno François(Inserm), SAATELLITE Study Group, Drieke Vandamme(Inserm), Filip Dubovsky(University of Maryland, Baltimore), Alexey Ruzin(AstraZeneca (United States)), Terramika Bellamy(AstraZeneca (United States)), Cédric Bretonnière(Inserm), D. Escudero, Omaima Ali, Jérôme Pugin(University Hospital of Geneva), Kathryn Shoemaker(AstraZeneca (United States)), Hasan S. Jafri(AstraZeneca (Australia)), Susan Colbert(AstraZeneca (United States)), Philippe Eggimann(University Hospital of Lausanne), Pierre‐François Dequin(Université de Tours), Miguel Sánchez(Stellenbosch University), Thierry Boulain(Centre hospitalier universitaire d'Orléans), P F Laterre(UCLouvain Saint-Louis Brussels), Vincent Huberlant(Centre Hospitalier Universitaire de Nantes)
Cited by 6
Related Papers
High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure
|New England Journal of Medicine|2015|2.4k
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19
|JAMA|2020|2.4k
Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit
|The Lancet Respiratory Medicine|2014|1.3k
The SOFA score—development, utility and challenges of accurate assessment in clinical trials
|Critical Care|2019|976
Hydrocortisone plus Fludrocortisone for Adults with Septic Shock
|New England Journal of Medicine|2018|894